Publication for TOP2A and PTTG1

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	TOP2A	DNA topoisomerase II alpha	7153			[link]
hsa	PTTG1	PTTG1 regulator of sister chromatid separation, securin	9232

Pubmed ID	Priority	Text
21844871	0.98	securin, TOP2A, cyclin B1 or control shRNA constructs were incubated with increasing doses of etoposide for 24h followed by flow cytometric analysis for determination of percentage of annexin V-positive cells.
	0.97	securin/pituitary tumor transforming gene1 (PTTG1), topoisomerase II alpha (TOP2A) and cyclin B1 (CCNB1), other genes shown to have increased expression at relapse.
	0.91	securin, TOP2A and cyclin B1 effectively reduce mRNA expression as determined by RT-PCR at 48 h after transfection.
	0.61	TOP2A, securin and survivin shRNA vectors reduced endogenous mRNA expression by 70-90%, respectively, as determined by quantitative RT-PCR at 48 h post-transfection (Figure 1a).
31322260	0.98	TOP2A, CDK1, CCNB1, CDKN3, BIRC5, AURKA, CCNB2, MAD2L1, HMMR, TTK, EZH2, CDC20, PTTG1, RACGAP1 and NCAPG (Table I).
21887332	0.97	PTTG1, Survivin and TOP2A subcellular staining in clinical tumor samples (-C: cytoplasmic staining; -N: nuclear staining).
	0.96	PTTG1, Survivin and TOP2A.
	0.96	PTTG1, Survivin and TOP2A in early stages (1-2) and advanced stages (3-4).
	0.93	TOP2A, PTTG1 and Survivin were chosen for further evaluation.
	0.92	TOP2A, PTTG1 and Survivin were chosen based on commercial availability of antibodies that had been validated in IHC.
	0.65	TOP2A were most distinct, compared to CDK1, PTTG1 and Survivin (Figure 4A).
	0.65	TOP2A, staining for CDK1, PTTG1, and Survivin was predominantly cytoplasmic.
31777591	0.97	TOP2A, EPRS, EXO1, PTTG1, RRM2, PSMD14, H2AFZ) were found to be promoter hypomethylated (Fig. 5) and 2 in 4 downregulated genes (EGFR, FGF2) were validated to be promoter hypermethylated (Fig. 6).
	0.95	TOP2A, MAD2L1, FEN1, EPRS, EXO1, MCM4, PTTG1, RRM2, PSMD14, CDKN3, H2AFZ, CCNE2) identified from GSE database were confirmed to be high expression genes in breast cancer (Fig. 2 and 3) (p<0.05) and 4 downregulated hub genes (EGFR, FGF2, BCL2, PIK3R1) confirmed to be low expression genes (Fig. 4) (p<0.05).
	0.95	TOP2A, MAD2L1, FEN1, EPRS (Fig. 7), EXO1, MCM4, PTTG1, RRM2 (Fig. 8), PSMD14, CDKN3, H2AFZ, CCNE2 (Fig. 9) and downregulation of FGF2, BCL2, PIK3R1 were significantly associated with poor overall survival, but downregulation of EGFR was not (Fig. 10).
	0.93	TOP2A; B: MAD2L1; C: FEN1; D: EPRS; E: EXO1; F: MCM4, G: PTTG1; H: RRM2; I: PSMD14; J: CDKN3; K: H2AFZ; L: CCNE2.
	0.88	TOP2A, MAD2L1, FEN1, EPRS, EXO1, MCM4, PTTG1, RRM2, PSMD14, CDKN3, H2AFZ, CCNE2) and 4 downregulated hub genes (EGFR, FGF2, BCL2, PIK3R1) might serve as diagnosis and poor prognosis biomarkers in breast cancer in the future by more research validation.
	0.62	TOP2A, MAD2L1, FEN1, EPRS, EXO1, MCM4, PTTG1, RRM2, PSMD14, CDKN3, H2AFZ, CCNE2 and downregulation of FGF2, BCL2, PIK3R1 might serve as diagnosis and poor prognosis biomarkers in breast cancer by more research validation.
31721906	0.97	PTTG1 (degree, 20.26), RACGAP (degree, 24.80), and TOP2A (degree, 29.14) (Table 2).
	0.83	PTTG1, RACGAP, and TOP2A were crucial genes with a high degree in the protein-protein interaction network.
31981472	0.97	PTTG1, and TOP2A) (p = 2.30182e-11).
	0.85	pituitary tumor transforming gene 1 (PTTG1, OMIM:604147), DNA topoisomerase II alpha (TOP2A, OMIM:126430), centromere protein U (CENPU, OMIM:611511), and UBE2T( OMIM:610538).
31422942	0.96	PTTG1, RRM2, TOP2A, UBE2C and UHRF1.
	0.95	PTTG1, RRM2, TOP2A, UHRF1, CEP55, BIRC5, UBE2C, FOXM1 and CDC20 indicated excellent diagnostic efficiency for tumor and normal tissues (Figure 8).
	0.95	PTTG1, RRM2, TOP2A, UHRF1, CEP55, BIRC5, UBE2C, FOXM1 and CDC20 are significantly upregulated in ccRCC compared with normal tissues (P < 0.01).
	0.86	PTTG1, RRM2, TOP2A, UHRF1, CEP55, BIRC5, UBE2C, FOXM1 and CDC20.
	0.75	PTTG1, (B) RRM2, (C) TOP2A, (D) UHRF1, (E) CEP55, (F) BIRC5, (G) UBE2C, (H) FOXM1, (I) CDC20.
31423162	0.96	PTTG1, RRM2, TK1, TOP2A, TPX2, TYMS, UBE2C, UBE2T, UHRF1, ZWINT) and considered to be the most relevant genes for breast cancer.
	0.96	PTTG1, TOP2A, TPX2, UBE2C and ZWINT) were present in MEblue.
	0.96	PTTG1, TOP2A, TPX2, UBE2C and ZWINT) that are closely associated with breast cancer were identified.
	0.94	pituitary tumor-transforming gene 1 protein (PTTG1), DNA topoisomerase 2alpha (TOP2A), targeting protein for Xklp2 (TPX2), ubiquitin-conjugating enzyme E2 C (UBE2C) and ZW10 interacting (ZWINT)] were considered hub genes and subjected to further analysis and validation.
26870179	0.96	PTTG1, along with CCNB1, CCNA2, SPC25, CENPF, NUSAP1, CDC20, TOP2A and BUB1, were observed to interact with each other (Fig. 1).
	0.68	PTTG1 interacted with other DEGs with higher connection degrees, such as CCNB1, CCNA2, SPC25, CENPF, NUSAP1, CDC20, TOP2A and BUB1.
	0.56	TOP2A and particularly PTTG1) and downregulated DEGs, such as those relevant to neuroactive ligand-receptor interaction (e.g., GABRA1, GABRA4 and GABRB1), as well as those correlated with the development of the pituitary gland, adenohypophysis and endocrine system (e.g., POU1F1) may have essential roles in the pathogenesis of pituitary adenomas.
31186759	0.95	TOP2A, PTTG1, GPC3 and PRC1) were identified to be associated with HCC.
	0.95	TOP2A, PTTG1, GPC3 and PRC1 genes were primarily involved in cell cycle, cell communication and protein metabolism biological processes.
	0.89	TOP2A, PTTG1, GPC3 and PRC1) was associated with poor overall survival of patients with HCC.
	0.87	TOP2A), pituitary tumor transforming gene 1 (PTTG1), glypican-3 (GPC3) and polycomb-repressive complex 1 (PRC1)], which were overlapped in three groups and were considered as candidate genes for selection of HCC biomarkers (Fig. 1A).
	0.82	TOP2A, PTTG1, GPC3 and PRC1 mRNA expression, and the red line represents HCC patients with high expression of the aforementioned genes.
27567667	0.95	PTTG1, CAP2, TOP2A, GPC3, EGR1, and NAT2) have been well studied in HCC (Table 1).
	0.93	PTTG1, TOP2A, GMNN, GPC3, UBE2C, UBAP2L, TBCE, and INTS8) were consistently and stably upregulated and 18 genes (CXCL14, VIPR1, CLEC4M, MARCO, CLEC1B, NAT2, FCN2, EGR1, DNASE1L3, MT1F, CRHBP, LCAT, PAMR1, ACSM3, MT1G, MT1X, SRPX, and MT1H) were consistently and stably downregulated in HCC, by least 2-fold (Fig. 1; Table 1).
	0.93	PTTG1, TBCE, TOP2A, UBE2C, and FCN2:encode proteins associated with cell cycle and microtubule cytoskeleton (Additional file 1: Table S1).
29159069	0.95	TOP2A, UHRF1, RAD51AP1, NR3C2, MCM6, PTTG1, NCAPG, CDCA5, UBE2C, PDGFD, RGS5, CEP55, CCNB2, CDKN3, CCDC109B, PTTG3P, RACGAP1, KIF20A, ALDH3A2, CDC20, EDNRB, and EMCN) (Fig. 3A).
30720105	0.95	PTTG1, pituitary tumor-transforming 1; CDC20, cell division cycle 20; TOP2A, DNA topoisomerase II alpha; CCNB2, cyclin B2.
18594525	0.94	TOP2A and IGF2 in our sample supports the reliability of the performed analyses and urges further evaluation of the prognostic value of securin in invasive breast cancer.
	0.91	topoisomerase DNA II alpha (TOP2A), securin and insulin-like growth factor 2 (somatomedin A (IGF2)).
21082037	0.94	PTTG1, ESPL1, TOP2A, NEK2, AURKA, TPX2, PLK1, etc.
28542306	0.94	TOP2A, KIAA0101, BIRC5, NUSAP1, CENPF, PRC1, ASPM, DTL), and 14 more CCP genes were upregulated in the MPNST vs. NF gene signature (FOXM1, TK1, CDC20, BUB1B, PBK, CDKN3, ASF1B, CEP55, DLGAP5, RAD51, KIF11, KIF20A, PTTG1, CDCA8).
31681566	0.92	TOP2A, and PTTG1) in NSCLC.
32153633	0.91	TOP2A, PLK1, MAD2L1, AURKA, BUB1B, UBE2C, TPX2, RRM2, KIF11, NCAPG, MELK, NUSAP1, MCM4, RFC4, PTTG1, CHEK1, CEP55, DTL) were selected by integrated analysis.
	0.87	TOP2A, PLK1, MAD2L1, AURKA, BUB1B, UBE2C, TPX2, RRM2, KIF11, NCAPG, MELK, NUSAP1, MCM4, RFC4, PTTG1, CHEK1, CEP55, and DTL.
24400072	0.91	TOP2A, CDC45L, AURKA, PRC1, KIFC1, PTTG1, AURKB, KIF23, KIF11, KIF20B, CENPE, ASPM, TTK, MAD2L1, NUF2, CDC20, CCNA2 and CCNB2, were highly expressed in CC1 MSCs compared to CC2 MSCs (Fig. 3C, Table 3).
29190974	0.85	PTTG1, SPC24, TOP2A, and ZWINT displayed different levels of upregulation (P<0.05).
32256749	0.81	TOP2A), CCNB2, kinesin family member (KIFC1), protein regulator of cytokinesis (PRC1), KIF20A, Rac GTPase-activating protein 1 (RACGAP1), PTTG1, ubiquitin-conjugating enzyme (UBE2C), maternal embryonic leucine zipper kinase (MELK), NUSAP1, cytoskeleton-associated protein 2 like (CKAP2L) and TK1.
23509795	0.79	TOP2A) and components of the mitotic spindle assembly checkpoint (the centromere constituents CENPE, the securin PTTG1, and MAD2L1, BUB1B, BUB3), genes related to pluripotency (e.g., LIN28 and TDGF1), large chromatin remodeling network genes (e.g., TOP2A, DNMT3B, JARID2, SMARCA5, CBX1, and CBX5), 18 different zinc finger transcription factors, including ZNF84, and several genes which are still poorly understood, such as KLHL7, MRS2, or the selenophosphate synthetase 1 (SEPHS1).
31527550	0.71	pituitary tumor-transforming gene 1 (PTTG1), ras homolog gene family, member A (RhoA), DNA topoisomerase II alpha (TOP2A), and vascular endothelial growth factor A (VEGF-A).